Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 10, Issue 1, Pages 23-28
Publisher
Informa UK Limited
Online
2016-11-24
DOI
10.1080/17474086.2017.1264268
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
- (2016) John Mascarenhas Clinical Lymphoma Myeloma & Leukemia
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
- (2016) A. A. Zahr et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
- (2016) A. A. Zahr et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
- (2015) N. Kroger et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
- (2015) Adam J. Mead et al. BRITISH JOURNAL OF HAEMATOLOGY
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- How many JAK inhibitors in myelofibrosis?
- (2014) Bruna Velosa Ferreira et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
- (2014) P. Guglielmelli et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- The future of JAK inhibition in myelofibrosis and beyond
- (2014) John O. Mascarenhas et al. BLOOD REVIEWS
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders
- (2011) Wanlong Ma et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
- (2011) N. C. P. Cross Hematology-American Society of Hematology Education Program
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- MPN-associated myelofibrosis (MPN-MF)
- (2010) R.A. Mesa et al. LEUKEMIA RESEARCH
- Prognostic factors in chronic myeloid leukaemia
- (2009) Juan Carlos Hernández-Boluda et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started